Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When do you consider disease modifying therapy in radiographically isolated syndrome?
Does reclassification of RIS as MS in upcoming McDonald Criteria change this decision for you?
Related Questions
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
What biomarkers best predict the response to B-cell depleting therapies in MS?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?